# A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure

> **NCT05451329** · PHASE2 · COMPLETED · sponsor: **VivaVision Biotech, Inc** · enrollment: 68 (actual)

## Conditions studied

- Glaucoma, Open-Angle

## Interventions

- **DRUG:** VVN539 Ophthalmic Solution 0.02%
- **DRUG:** VVN539 Ophthalmic Solution 0.04%
- **DRUG:** VVN539 Ophthalmic Solution Vehicle

## Key facts

- **NCT ID:** NCT05451329
- **Lead sponsor:** VivaVision Biotech, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-12
- **Primary completion:** 2022-12-22
- **Final completion:** 2022-12-22
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2024-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05451329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05451329, "A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05451329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*